Vectus Biosystems (ASX:VBS) Tariff Resilience Score: 0/10 (As of Jul. 03, 2026)


ASX:VBS Vectus Biosystems Ltd ASX:VBS
18 GF Score
Price A$0.12
! 2 Warning Signs
View Full Analysis

What is Vectus Biosystems Tariff Resilience Score?

Vectus Biosystems has the Tariff Resilience Score of 0, which implies that the company might have .

Vectus Biosystems has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Vectus Biosystems might have .

Vectus Biosystems  (ASX:VBS) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Vectus Biosystems Tariff Resilience Score Related Terms

ASX:VBS
18GF Score
Vectus Biosystems Ltd ASX:VBS
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectus Biosystems Business Description

Address 26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
18GF Score

Get the complete analysis for ASX:VBS

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price